Latest News and Press Releases

BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to...

60 Degrees Pharma unveils “B-FREE” Phase 2 trial for chronic babesiosis, engaging patients in naming and supporting Lyme research groups.

BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM) and Topline Phase 2b clinical data expected in 1H 2026

Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "CD5 Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025" report has been added to ...

MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on...

– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting – – IND clearance expands Company’s advanced clinical pipeline...

Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "CD70 Targeting Therapies Clinical Trials & Market Opportunity Insight 2025" report has been added to ResearchAndMarkets.com's offering. CD70...

Company To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-Cap HANOVER, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) --...

Multi-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...

--Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100--  MELVILLE, N.Y., June 12, 2023 (GLOBE NEWSWIRE) --...